Shilpa Medicare Management
Management criteria checks 4/4
Shilpa Medicare's CEO is Vishnukanth Bhutada, appointed in Aug 2022, has a tenure of 2.25 years. total yearly compensation is ₹35.00M, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 8.87% of the company’s shares, worth ₹6.88B. The average tenure of the management team and the board of directors is 2.5 years and 3.2 years respectively.
Key information
Vishnukanth Bhutada
Chief executive officer
₹35.0m
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 2.3yrs |
| CEO ownership | 8.9% |
| Management average tenure | 2.5yrs |
| Board average tenure | 3.2yrs |
Recent management updates
Recent updates
What Shilpa Medicare Limited's (NSE:SHILPAMED) 28% Share Price Gain Is Not Telling You
Sep 12
Shilpa Medicare Limited's (NSE:SHILPAMED) 29% Price Boost Is Out Of Tune With Revenues
Jul 05What Shilpa Medicare Limited's (NSE:SHILPAMED) 27% Share Price Gain Is Not Telling You
Apr 12Shilpa Medicare Limited's (NSE:SHILPAMED) Shares Climb 28% But Its Business Is Yet to Catch Up
Feb 21Shilpa Medicare (NSE:SHILPAMED) Takes On Some Risk With Its Use Of Debt
Jan 02These 4 Measures Indicate That Shilpa Medicare (NSE:SHILPAMED) Is Using Debt Extensively
Jul 17Shilpa Medicare (NSE:SHILPAMED) Seems To Be Using A Lot Of Debt
Mar 17Increases to CEO Compensation Might Be Put On Hold For Now at Shilpa Medicare Limited (NSE:SHILPAMED)
Sep 22Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10
Sep 07Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10
Aug 14Here's Why Shilpa Medicare (NSE:SHILPAMED) Is Weighed Down By Its Debt Load
Jan 27Shareholders May Not Be So Generous With Shilpa Medicare Limited's (NSE:SHILPAMED) CEO Compensation And Here's Why
Sep 21Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?
Jun 17If You Like EPS Growth Then Check Out Shilpa Medicare (NSE:SHILPAMED) Before It's Too Late
May 31Shilpa Medicare Limited's (NSE:SHILPAMED) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Mar 07Shilpa Medicare Limited (NSE:SHILPAMED) Analysts Are Reducing Their Forecasts For Next Year
Feb 20Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?
Jan 26
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹611m |
| Jun 30 2024 | n/a | n/a | ₹448m |
| Mar 31 2024 | ₹35m | ₹35m | ₹319m |
| Dec 31 2023 | n/a | n/a | -₹7m |
| Sep 30 2023 | n/a | n/a | -₹119m |
| Jun 30 2023 | n/a | n/a | -₹321m |
| Mar 31 2023 | ₹35m | ₹35m | -₹325m |
| Dec 31 2022 | n/a | n/a | ₹51m |
| Sep 30 2022 | n/a | n/a | ₹213m |
| Jun 30 2022 | n/a | n/a | ₹599m |
| Mar 31 2022 | ₹97m | ₹16m | ₹607m |
| Dec 31 2021 | n/a | n/a | ₹395m |
| Sep 30 2021 | n/a | n/a | ₹376m |
| Jun 30 2021 | n/a | n/a | ₹631m |
| Mar 31 2021 | ₹97m | ₹16m | ₹1b |
| Dec 31 2020 | n/a | n/a | ₹2b |
| Sep 30 2020 | n/a | n/a | ₹2b |
| Jun 30 2020 | n/a | n/a | ₹2b |
| Mar 31 2020 | ₹99m | ₹10m | ₹2b |
| Dec 31 2019 | n/a | n/a | ₹1b |
| Sep 30 2019 | n/a | n/a | ₹1b |
| Jun 30 2019 | n/a | n/a | ₹944m |
| Mar 31 2019 | ₹75m | ₹10m | ₹1b |
| Dec 31 2018 | n/a | n/a | ₹1b |
| Sep 30 2018 | n/a | n/a | ₹1b |
| Jun 30 2018 | n/a | n/a | ₹1b |
| Mar 31 2018 | ₹81m | ₹16m | ₹1b |
Compensation vs Market: Vishnukanth's total compensation ($USD414.61K) is about average for companies of similar size in the Indian market ($USD354.64K).
Compensation vs Earnings: Vishnukanth's compensation has been consistent with company performance over the past year.
CEO
Vishnukanth Bhutada (62 yo)
2.3yrs
Tenure
₹35,000,000
Compensation
Mr. Vishnukanth Chaturbhuj Bhutada, B. Pharm. serves as the Managing Director of Shilpa Medicare Limited since August 11, 2022 . Mr. Bhutada joined Shilpa Medicare Limited in November 1987.He serves as th...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Director | 2.3yrs | ₹35.00m | 8.87% ₹ 6.9b | |
| Chief Financial Officer | 3.5yrs | ₹14.73m | 0.0023% ₹ 1.8m | |
| VP of Projects & Operations and Whole-Time Director | no data | ₹16.26m | 0.032% ₹ 25.1m | |
| Company Secretary & Compliance Officer | 2.5yrs | ₹4.51m | no data | |
| Chief Operating Officer of Formulations | no data | ₹26.95m | no data | |
| President of Global R&D | no data | ₹11.50m | no data | |
| Senior Vice President – Domestic Formulations and Biologics | no data | ₹3.90m | no data | |
| Senior Vice President of Formulation | no data | ₹12.50m | no data | |
| Executive Vice President – Formulations for Small Molecules | no data | ₹2.50m | no data | |
| Vice President | no data | ₹12.77m | no data | |
| Senior Vice President of Technical | no data | ₹6.06m | no data | |
| Chief Human Resource Officer | no data | no data | no data |
2.5yrs
Average Tenure
53.5yo
Average Age
Experienced Management: SHILPAMED's management team is considered experienced (2.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD & Director | 37yrs | ₹35.00m | 8.87% ₹ 6.9b | |
| VP of Projects & Operations and Whole-Time Director | 5.1yrs | ₹16.26m | 0.032% ₹ 25.1m | |
| Non-Executive Independent Director | 3.2yrs | ₹3.00m | no data | |
| Non-Executive Independent Director | 2.3yrs | ₹3.00m | no data | |
| Non-Executive Independent Director | 3.2yrs | ₹4.00m | 0.0092% ₹ 7.1m | |
| Non-Executive Chairman | 36.7yrs | ₹350.00k | 3.3% ₹ 2.6b | |
| Independent Women Director | 2.3yrs | ₹1.80m | no data |
3.2yrs
Average Tenure
62yo
Average Age
Experienced Board: SHILPAMED's board of directors are considered experienced (3.2 years average tenure).